The pathophysiology of HF is associated with persistent activation of the renin-angiotensin-aldosterone system (RAAS), and drugs that inhibit key components of the RAAS are therefore introduced into the clinical pharmacotherapy of HF [6]. Here, REN is linked to hydrops fetalis.